The beneficial role of Asian-based RecurIndex test in the prognostic prediction in Chinese male breast cancer patients
Abstract RecurIndex, a multigene profiling assay, can predict the risk of local recurrence and distant metastasis in female breast cancer (FBC), but its role in male breast cancer (MBC) remains unclear. In this study, the clinicopathological data of 43 consecutive MBC patients undergoing surgeries b...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2021-04-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-021-87267-y |
| _version_ | 1818841424071753728 |
|---|---|
| author | Shuo Zhang Beichen Liu Mengli Zhou Jintian Wang Jinzhao Liu Li Wang Chao Yang Yueping Liu Shuyao Niu Furong Du Xiaohua Du Ning Wang Jiyu Tang Chao Song Yunjiang Liu |
| author_facet | Shuo Zhang Beichen Liu Mengli Zhou Jintian Wang Jinzhao Liu Li Wang Chao Yang Yueping Liu Shuyao Niu Furong Du Xiaohua Du Ning Wang Jiyu Tang Chao Song Yunjiang Liu |
| author_sort | Shuo Zhang |
| collection | DOAJ |
| description | Abstract RecurIndex, a multigene profiling assay, can predict the risk of local recurrence and distant metastasis in female breast cancer (FBC), but its role in male breast cancer (MBC) remains unclear. In this study, the clinicopathological data of 43 consecutive MBC patients undergoing surgeries between 2009 and 2018 were retrospectively analysed. Their paraffin-embedded tissue sections were examined by RecurIndex test which comprised 2 models: recurrence index for local recurrence (RI-LR) and recurrence index for distant recurrence (RI-DR). Of 43 patients, there were 26 low-risk and 17 high-risk patients assessed by RI-LR, while 17 low-risk and 26 high-risk patients by RI-DR. For RI-LR, tumor N stage showed statistically significant (P < 0.001) between low- and high-risk patients; for RI-DR, differences were pronounced in tumor grade (P = 0.033), T stage (P = 0.043) and N stage (P = 0.003). In terms of clinical outcomes, the overall survival (OS) of low- and high-risk patients stratified by RI-LR showed no statistically significant differences (P = 0.460), while high-risk patients identified by RI-DR had a significantly worse distant recurrence-free survival (DRFS) (P = 0.035), progression-free survival (PFS) (P = 0.019) and OS (P = 0.044) than low-risk patients. Overall, RI-DR can effectively predict the DRFS, PFS and OS of MBC patients and identify those at low risk of recurrence, which may serve as a potential prognostic tool for MBC. |
| first_indexed | 2024-12-19T04:25:51Z |
| format | Article |
| id | doaj.art-b8f9bf0eb917417294743488db621f33 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-12-19T04:25:51Z |
| publishDate | 2021-04-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-b8f9bf0eb917417294743488db621f332022-12-21T20:36:02ZengNature PortfolioScientific Reports2045-23222021-04-011111810.1038/s41598-021-87267-yThe beneficial role of Asian-based RecurIndex test in the prognostic prediction in Chinese male breast cancer patientsShuo Zhang0Beichen Liu1Mengli Zhou2Jintian Wang3Jinzhao Liu4Li Wang5Chao Yang6Yueping Liu7Shuyao Niu8Furong Du9Xiaohua Du10Ning Wang11Jiyu Tang12Chao Song13Yunjiang Liu14Breast Center, The Fourth Hospital of Hebei Medical UniversityDepartment of Haematology, The Fourth Hospital of Hebei Medical UniversityThe State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd.Breast Center, The Fourth Hospital of Hebei Medical UniversityBreast Center, The Fourth Hospital of Hebei Medical UniversityDepartment of Breast Surgery, Xingtai People’s HospitalBreast Center, The Fourth Hospital of Hebei Medical UniversityDepartment of Pathology, The Fourth Hospital of Hebei Medical UniversityDepartment of Pathology, The Fourth Hospital of Hebei Medical UniversityThe State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd.The State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd.The State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd.The State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd.The State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd.Breast Center, The Fourth Hospital of Hebei Medical UniversityAbstract RecurIndex, a multigene profiling assay, can predict the risk of local recurrence and distant metastasis in female breast cancer (FBC), but its role in male breast cancer (MBC) remains unclear. In this study, the clinicopathological data of 43 consecutive MBC patients undergoing surgeries between 2009 and 2018 were retrospectively analysed. Their paraffin-embedded tissue sections were examined by RecurIndex test which comprised 2 models: recurrence index for local recurrence (RI-LR) and recurrence index for distant recurrence (RI-DR). Of 43 patients, there were 26 low-risk and 17 high-risk patients assessed by RI-LR, while 17 low-risk and 26 high-risk patients by RI-DR. For RI-LR, tumor N stage showed statistically significant (P < 0.001) between low- and high-risk patients; for RI-DR, differences were pronounced in tumor grade (P = 0.033), T stage (P = 0.043) and N stage (P = 0.003). In terms of clinical outcomes, the overall survival (OS) of low- and high-risk patients stratified by RI-LR showed no statistically significant differences (P = 0.460), while high-risk patients identified by RI-DR had a significantly worse distant recurrence-free survival (DRFS) (P = 0.035), progression-free survival (PFS) (P = 0.019) and OS (P = 0.044) than low-risk patients. Overall, RI-DR can effectively predict the DRFS, PFS and OS of MBC patients and identify those at low risk of recurrence, which may serve as a potential prognostic tool for MBC.https://doi.org/10.1038/s41598-021-87267-y |
| spellingShingle | Shuo Zhang Beichen Liu Mengli Zhou Jintian Wang Jinzhao Liu Li Wang Chao Yang Yueping Liu Shuyao Niu Furong Du Xiaohua Du Ning Wang Jiyu Tang Chao Song Yunjiang Liu The beneficial role of Asian-based RecurIndex test in the prognostic prediction in Chinese male breast cancer patients Scientific Reports |
| title | The beneficial role of Asian-based RecurIndex test in the prognostic prediction in Chinese male breast cancer patients |
| title_full | The beneficial role of Asian-based RecurIndex test in the prognostic prediction in Chinese male breast cancer patients |
| title_fullStr | The beneficial role of Asian-based RecurIndex test in the prognostic prediction in Chinese male breast cancer patients |
| title_full_unstemmed | The beneficial role of Asian-based RecurIndex test in the prognostic prediction in Chinese male breast cancer patients |
| title_short | The beneficial role of Asian-based RecurIndex test in the prognostic prediction in Chinese male breast cancer patients |
| title_sort | beneficial role of asian based recurindex test in the prognostic prediction in chinese male breast cancer patients |
| url | https://doi.org/10.1038/s41598-021-87267-y |
| work_keys_str_mv | AT shuozhang thebeneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients AT beichenliu thebeneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients AT menglizhou thebeneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients AT jintianwang thebeneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients AT jinzhaoliu thebeneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients AT liwang thebeneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients AT chaoyang thebeneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients AT yuepingliu thebeneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients AT shuyaoniu thebeneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients AT furongdu thebeneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients AT xiaohuadu thebeneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients AT ningwang thebeneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients AT jiyutang thebeneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients AT chaosong thebeneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients AT yunjiangliu thebeneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients AT shuozhang beneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients AT beichenliu beneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients AT menglizhou beneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients AT jintianwang beneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients AT jinzhaoliu beneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients AT liwang beneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients AT chaoyang beneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients AT yuepingliu beneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients AT shuyaoniu beneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients AT furongdu beneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients AT xiaohuadu beneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients AT ningwang beneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients AT jiyutang beneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients AT chaosong beneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients AT yunjiangliu beneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients |